RecruitingNCT07459686

An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis

Velsipity® Tablets 2 mg Special Investigation (Investigation on Long-Term Use in Patients With Ulcerative Colitis)

Sponsor

Pfizer

Enrollment

553 participants

Start Date

Apr 27, 2026

Study Type

OBSERVATIONAL

Conditions

Ulcerative Colitis (UC)

Summary

A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.

Eligibility

Min Age: 0 Years

Inclusion Criteria2

Patients with moderate to severe ulcerative colitis for whom treatment with this drug was started for the first time after the contract date for this study. Patients who have participated in a clinical study of this drug in the past or patients who have participated in this study are excluded.
Patients who understand the contents of this study and give consent to provision of the information collected in this study to third parties and the use of it for other purposes.

Interested in this trial?

Get notified about updates and connect with the research team.